RPTX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
RPTX Current Performance
1.03%
Repare therapeutics inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to RPTX
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
ARVN | Arvinas inc | 2 | 3 | 3 | 3 | 1 | |
EDIT | Editas medicine inc | 3 | 3 | 2 | 2 | 1 | |
TXMD | Therapeuticsmd incorporated | 4 | 1 | 2 | 1 | 1 | |
NTLA | Intellia therapeutics inc | 4 | 3 | 2 | 3 | 1 | |
MURA | Mural oncology plc | - | 3 | 2 | - | 1 |
- ARVN Arvinas incValue 2Trend 3Swing Trading 3Whale Interest 3Dividend 1See more
RPTX Profile
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company's initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.